Want to see ATR full AI Analyst Report?
ATR Stock Chart & Stats
$130.63
-$0.05(-0.03%)
At close: 4:00 PM EST
$130.63
-$0.05(-0.03%)
Day’s Range― - ―
52-Week Range$103.23 - $164.28
Previous CloseN/A
Volume34.64K
Average Volume (3M)524.16K
Market Cap
$8.10B
Enterprise Value$8.84B
Total Cash (Recent Filing)$229.48M
Total Debt (Recent Filing)$1.41B
Price to Earnings (P/E)21.5
Beta0.55
Next Earnings
Jul 30, 2026EPS Estimate
1.36Next Dividend Ex-DateN/A
Dividend Yield1.5%
Share Statistics
EPS (TTM)5.91
Shares Outstanding63,820,316
10 Day Avg. Volume504,938
30 Day Avg. Volume524,165
Financial Highlights & Ratios
PEG Ratio3.61
Price to Book (P/B)3.01
Price to Sales (P/S)2.12
P/FCF Ratio26.76
Enterprise Value/Market Cap1.09
Enterprise Value/Revenue2.28
Enterprise Value/Gross Profit7.88
Enterprise Value/Ebitda10.59
Forecast
1Y Price Target
$139.75Price Target Upside6.98% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
EPS Forecast (FY)5.51
Revenue Forecast (FY)$3.98B
Bulls Say, Bears Say
Bulls Say
Recurring, Diversified Revenue ModelAptar’s core business sells proprietary dispensing and drug‑delivery components across healthcare, beauty and food. Pharma programs require engineering, regulatory-grade manufacturing and long qualification, creating multi-year commercial supply, recurring revenue and higher switching costs that support durable revenue visibility.
Strong Cash Generation And Rising Free Cash FlowSustained operating cash flow and growing free cash flow provide internal funding for capex, R&D and shareholder returns. FCF covering roughly half of net income and recent year‑over‑year improvement gives financial flexibility to finance investments or reduce leverage without relying solely on external capital.
Pharma Pipeline, Approvals And Commercial WinsConcrete regulatory milestones and program wins validate Aptar’s drug‑delivery tech and create multi‑year supply opportunities. Approvals (originator and generic MDI valve validation) and pipeline progress signal durable demand in pharma, which tends to lock in suppliers and supports higher value, longer‑term contracts.
Bears Say
TTM Equity Erosion And High Leverage SignalAnomalously low TTM equity sharply increases leverage ratios and elevates refinancing, covenant and liquidity risks. Even with historically moderate annual leverage, a sustained erosion of equity reduces financial flexibility, raises interest sensitivity and constrains strategic options until capital structure is rebuilt.
Sharp TTM Gross-margin DeclineA material gross‑margin step‑down indicates cost, mix or pricing pressure that can persistently lower operating profitability. If structural (raw materials, mix shift, or pass‑through timing), it reduces margin sustainability and free cash flow, forcing either price increases, efficiency actions, or margin tradeoffs that affect long‑term earnings quality.
Emergency Medicine Destocking Hitting Near-term Pharma SalesA sizeable, company‑disclosed destocking event reduces near‑term revenue visibility in a key pharma subsegment and depresses utilization and margin recovery. The multi‑quarter timing of the hit can delay realization of pipeline benefits and compress segment profit near term, complicating operational planning and cash conversion.
AptarGroup News
ATR FAQ
What was AptarGroup, Inc.’s price range in the past 12 months?
AptarGroup, Inc. lowest stock price was $103.23 and its highest was $164.28 in the past 12 months.
What is AptarGroup, Inc.’s market cap?
AptarGroup, Inc.’s market cap is $8.10B.
When is AptarGroup, Inc.’s upcoming earnings report date?
AptarGroup, Inc.’s upcoming earnings report date is Jul 30, 2026 which is in 26 days.
How were AptarGroup, Inc.’s earnings last quarter?
AptarGroup, Inc. released its earnings results on Apr 30, 2026. The company reported $1.19 earnings per share for the quarter, beating the consensus estimate of $1.15 by $0.04.
Is AptarGroup, Inc. overvalued?
According to Wall Street analysts AptarGroup, Inc.’s price is currently Undervalued.
Does AptarGroup, Inc. pay dividends?
AptarGroup, Inc. pays a Quarterly dividend of $0.48 which represents an annual dividend yield of 1.5%. See more information on AptarGroup, Inc. dividends here
What is AptarGroup, Inc.’s EPS estimate?
AptarGroup, Inc.’s EPS estimate is 1.36.
How many shares outstanding does AptarGroup, Inc. have?
AptarGroup, Inc. has 63,820,316 shares outstanding.
What happened to AptarGroup, Inc.’s price movement after its last earnings report?
AptarGroup, Inc. reported an EPS of $1.19 in its last earnings report, beating expectations of $1.15. Following the earnings report the stock price went down -3.768%.
Which hedge fund is a major shareholder of AptarGroup, Inc.?
Currently, no hedge funds are holding shares in ATR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
AptarGroup Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$139.75 (6.98% Upside)
$139.75 (6.98% Upside)
Blogger Sentiment
Bullish
ATR Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 709.0 Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.8%
Last 30 Days ▲ 2.1%
Last 30 Days ▲ 2.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-19.65%
12-Months-Change
Fundamentals
Return on Equity
14.33%
Trailing 12-Months
Asset Growth
12.61%
Trailing 12-Months
Company Description
AptarGroup, Inc.
AptarGroup, Inc. specializes in developing and manufacturing solutions for dispensing, sealing, and advanced material science, catering to a broad spectrum of industries such as beauty, personal care, home care, and the pharmaceutical sector (including prescription drugs, consumer health care, and injectables), alongside the food and beverage markets. Its operations are structured into three key segments: Pharma, Beauty + Home, and Food + Beverage. The Pharma division offers critical components for the pharmaceutical industry, including pumps for nasal allergy remedies, metered dose inhaler valves vital for managing respiratory conditions like asthma and chronic obstructive pulmonary disease (COPD), elastomeric primary packaging for injectables, and sophisticated active material science innovations. The Beauty + Home segment primarily supplies the personal care and home care sectors with essential products such as pumps, various closures, aerosol valves, accompanying accessories, and sealing mechanisms. It also furnishes the beauty market with pumps and decorative elements. For the food and beverage industries, its Food + Beverage segment delivers a variety of dispensing and non-dispensing closures, specialized elastomeric flow control components, spray pumps, and aerosol valves. AptarGroup markets its offerings globally, utilizing its internal sales team, complemented by independent representatives and distributors across Asia, Europe, Latin America, and North America. The company is engaged in a strategic partnership with PureCycle Technologies LLC to pioneer the integration of ultra-pure recycled polypropylene into advanced dispensing applications. Additionally, it collaborates with Sonmol on the development of a digital platform providing therapies and services, with a particular focus on respiratory and other health conditions. Established in 1992, AptarGroup, Inc. maintains its corporate headquarters in Crystal Lake, Illinois.
ATR Company Deck
ATR Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a balanced picture: solid cash generation, product wins, meaningful pharma pipeline progress and targeted investments underpin medium-to-long-term growth. However, near-term headwinds—most notably a ~$65 million emergency medicine destock, margin compression across segments (Beauty and Closures), operational disruptions, and rising input costs—create tangible short-term pressure on profitability. Management expects sequential improvement and has provided a Q2 EPS range and full-year investment outlook, but near-term metrics reflect a mix of positive commercial momentum and notable operational and cost challenges.View all ATR earnings summariesATR Stock 12 Month Forecast
Average Price Target
$139.75
▲(6.98% Upside)
Technical Analysis
Baxter International
―
Cooper Co
―
Repligen
―
West Pharmaceutical Services
―
Stevanato Group
―
Ownership Overview
0.78% Insiders
31.04% Mutual Funds
0.25% Other Institutional Investors
41.87% Public Companies and
Individual Investors